News tagged with 'Weight Loss'

Liraglutide shows promise in helping patients, even those without diabetes, lose weight says maker Novo Nordisk which is hoping for FDA approval. Both it and rival, Alli are being studied for their side effects.

Onexa, a new experimental obesity drug by Vivus Inc., of Mountain View California, met key weight loss goals in two late-stage studies.

Alli and Xenical, the same drug with different strengths, are available to help people fight weight gain. The benefit may not offset liver damage, which the FDA is investigating.

Hydroxycut weight loss and energy products are off the market after an FDA warning linking them to liver damage and death.  The multi-millionaire founder, now facing a slew of lawsuits, at one point was making $350 million a year on his untested products. 

The FDA is issuing its third alert concerning over-the-counter weight loss products that contain prescription ingredients. A diuretic, anti-seizure, and prescription-only appetite supressant have been found in these OTC drugs the FDA wants taken off the market. 

When it comes to losing weight, one diet is no better than the next. It doesn't matter where your calories come from, as long as you're eating less, suggests a new study in the New England Journal of Medicine.

Obesity is considered a risk factor for a variety of ills, so choosing a diet plan from this Top 10 Healthiest Diets list might make weight loss a bit more pleasant as well as effective.    

A new study suggests, when financial rewards are involved, losing weight becomes easier. Researchers found weight-loss programs that financially reward participants provided a powerful incentive to lose weight, when compared to conventional approaches.

A new study published in the journal Cell Metabolism finds an experimental drug, by GlaxoSmithKline, that imitates a health-boosting compound found in red wine may offer promise in the fight against diabetes and obesity, according to researchers.

The European Medicines Agency (EMEA) has recommended the suspension of Acomplia (rimonabant) from Sanofi-Aventis. The agency concluded that the benefits of Acomplia no longer outweigh its risks and marketing should be suspended across the European Union (EU).

Researchers followed a group of moderately obese dieters placed on one of three diets - a Mediterranean diet; a low-carbohydrate diet based on Atkins; and a diet with 30 percent fat based on American Heart Association guidelines. The study findings determined low-carbohydrate diets were most effective.